The Scottish Medicines Consortium (SMC) has issued guidance not to recommend Imnovid (pomalidomide) in combination with low-dose dexamethasone for use in relapsed and refractory myeloma patients who have received prior treatment with Velcade® and Revlimid® and have demonstrated disease progression on their last treatment. Although the SMC acknowledged that pomalidomide was clinically significant in this patient group, the high cost of the drug in relation to its benefits meant that it was not considered to be cost effective. Pomalidomide is currently being assessed by the National Institute for Health and Care Excellence (NICE) for myeloma patients in England where a decision is expected early next year.

Read the full article